COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > Synthetic Chemistry Research Interest Group > NEW drugs from OLD pathways - Teaching Nature New Tricks
NEW drugs from OLD pathways - Teaching Nature New TricksAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact hk457. Born in Dollar and educated at Alloa Academy, Tom Simpson graduated (BSc Edinburgh) in 1969 and (PhD Bristol) in 1973. After post-doctoral work in Liverpool and Canberra (ANU), he was appointed Lecturer in Edinburgh in 1978. He moved to Leicester in 1988, at the time the youngest Professor of Organic Chemistry in the UK, and then to Bristol in 1990. He has been awarded the Royal Society of Chemistry Corday-Morgan and Natural Products Chemistry medals and the Tilden, Simonsen and Hugo Muller lectureships and, most recently, the Rita and John Cornforth Award for interdisciplinary research and the Robert Robinson Lectureship. He works on the chemistry and biosynthesis of biologically important microbial natural products. Elected FRS in 2001, FRSE in 2006, and received an Honorary D.Sc. from Edinburgh in 2015. NEW drugs from OLD pathways – Teaching Nature New Tricks. Tom Simpson, School of Chemistry, University of Bristol Engineering metabolic pathways in microorganisms can provide new antibiotics and other bioactive natural products. The mupirocins, e.g. pseudomonic acid A and thiomarinols isolated from Pseudomonas and Pseudoalteromonas bacteria are antibiotics active against MRSA . Clinical applications are restricted by instability in the former and toxicity in the latter. Using classical biosynthetic methods to understand how they are formed, combined with molecular genetic engineering, novel analogues in which both these limitations are overcome can be produced. Similarly, the biosynthetic pathway to the fungal metabolite, tenellin, isolated from Beauvaria bassiana, has been engineered to produce the “extinct” compound, bassianin, and many new compounds for biological evaluation. This talk is part of the Synthetic Chemistry Research Interest Group series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsWellcome Genome Campus Society and Ethics seminars Cambridge Statistics Discussion Group (CSDG) Caius-Trinity MedSoc Talks: The Future of MedicineOther talksBioengineering approach to atherosclerosis and aneurysm rupture and clinical implications gloknos Annual Lecture Series in conjunction with the CSAS Seminar Series: In the Bay of Bengal: modelling empire, globe and self The Class Ceiling: Why it Plays to be Privileged Perception of Visual Space Are Your Selfies Carbon-Neutral? Human Rights and the Environmental Impact of Digital Technology Cancers and the tumour microenvironment |